利妥昔单抗治疗原发性干燥综合征疲劳与口干:随机对照试验及成本效果分析
这项多中心随机双盲安慰剂对照试验纳入133例抗Ro阳性、有症状性疲劳和口干的原发性干燥综合征患者,比较静脉利妥昔单抗与安慰剂。48周时主要终点(疲劳或口干视觉模拟评分下降30%)应答率两组无显著差异,调整OR为1.13(95%CI 0.50, 2.55),除非刺激唾液流率外无其他显著改善;利妥昔单抗人均费用更高,结论为在该人群中既无临床效果也无成本效果。
要点
- 利妥昔单抗未显著改善原发性干燥综合征的疲劳或口干症状。
- 48周主要终点应答率:安慰剂36.8% vs 利妥昔单抗39.8%,调整OR 1.13(95%CI 0.50, 2.55)。
- 除非刺激唾液流率外,其他次要结局均无显著改善,且利妥昔单抗人均费用更高。
核心结论
- 利妥昔单抗在该原发性干燥综合征患者人群中既无临床效果也无成本效果。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照、平行组试验,含健康经济学分析,从英国25家风湿科门诊招募抗Ro阳性、有症状性疲劳和口干的原发性干燥综合征患者。
- 133例患者随机接受静脉安慰剂(250 ml生理盐水,n=66)或静脉利妥昔单抗(1,000 mg溶于250 ml生理盐水,n=67),于第0、2、24、26周分2个疗程给药,并给予输注前后药物包括糖皮质激素。
主要发现
- 在完整数据患者中,安慰剂组56例中21例、利妥昔单抗组61例中24例达到主要终点。
- 对缺失结局进行多重插补后,安慰剂组和利妥昔单抗组应答率分别为36.8%和39.8%,调整比值比1.13(95%置信区间0.50, 2.55)。
- 除非刺激唾液流率外,任何其他结局指标均无显著改善。
- 利妥昔单抗和安慰剂组每例患者平均费用分别为£10,752 ± 264.75和£2,672 ± 241.71。
- 利妥昔单抗组报告的不良事件总数略多,但严重不良事件无差异(每组10例)。
关键数值与推荐
- 主要终点为48周时疲劳或口干(视觉模拟评分)下降30%的患者比例。
- 其他结局包括唾液和泪液流率、生活质量、EULAR干燥综合征患者报告指数和EULAR干燥综合征疾病活动指数评分、眼干和整体干燥症状、疼痛、总体疾病活动度及成本效果。
临床怎么用
- 对于抗Ro阳性、以疲劳和口干为主诉的原发性干燥综合征患者,利妥昔单抗不应作为改善这些症状的常规选择。
- 临床决策需考虑利妥昔单抗的高昂费用及其在该人群中缺乏临床获益的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjögren's syndrome (SS). METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that included health economic analysis. Anti-Ro-positive patients with primary SS, symptomatic fatigue, and oral dryness were recruited from 25 UK rheumatology clinics from August 2011 to January 2014. Patients were centrally randomized to receive either intravenous (IV) placebo (250 ml saline) or IV rituximab (1,000 mg in 250 ml saline) in 2 courses at weeks 0, 2, 24, and 26, with pre- and postinfusion medication including corticosteroids. The primary end point was the proportion of patients achieving a 30% reduction in either fatigue or oral dryness at 48 weeks, as measured by visual analog scale. Other outcome measures included salivary and lacrimal flow rates, quality of life, scores on the European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index and EULAR Sjögren's Syndrome Disease Activity Index, symptoms of ocular and overall dryness, pain, globally assessed disease activity, and cost-effectiveness. RESULTS: All 133 patients who were randomized to receive placebo (n = 66) or rituximab (n = 67) were included in the primary analysis. Among patients with complete data, 21 of 56 placebo-treated patients and 24 of 61 rituximab-treated patients achieved the primary end point. After multiple imputation of missing outcomes, response rates in the placebo and rituximab groups were 36.8% and 39.8%, respectively (adjusted odds ratio 1.13 [95% confidence interval 0.50, 2.55]). There were no significant improvements in any outcome measure except for unstimulated salivary flow. The mean ± SD costs per patient for rituximab and placebo were £10,752 ± 264.75 and £2,672 ± 241.71, respectively. There were slightly more adverse events (AEs) reported in total for rituximab, but there was no difference in serious AEs (10 in each group). CONCLUSION: The results of this study indicate that rituximab is neither clinically effective nor cost-effective in this patient population.
引用
- Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis Rheumatol. 2017. PMID: 28296257. doi:10.1002/art.40093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。